Success Metrics

Clinical Success Rate
86.4%

Based on 19 completed trials

Completion Rate
86%(19/22)
Active Trials
2(6%)
Results Posted
5%(1 trials)
Terminated
3(8%)

Phase Distribution

Ph phase_4
6
17%
Ph phase_2
10
28%
Ph phase_1
6
17%
Ph not_applicable
2
6%
Ph phase_3
11
31%
Ph early_phase_1
1
3%

Phase Distribution

7

Early Stage

10

Mid Stage

17

Late Stage

Phase Distribution36 total trials
Early Phase 1First-in-human
1(2.8%)
Phase 1Safety & dosage
6(16.7%)
Phase 2Efficacy & side effects
10(27.8%)
Phase 3Large-scale testing
11(30.6%)
Phase 4Post-market surveillance
6(16.7%)
N/ANon-phased studies
2(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.0%

19 of 25 finished

Non-Completion Rate

24.0%

6 ended early

Currently Active

2

trials recruiting

Total Trials

36

all time

Status Distribution
Active(4)
Completed(19)
Terminated(6)
Other(7)

Detailed Status

Completed19
unknown6
Withdrawn3
Terminated3
Enrolling by invitation2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
36
Active
2
Success Rate
86.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.8%)
Phase 16 (16.7%)
Phase 210 (27.8%)
Phase 311 (30.6%)
Phase 46 (16.7%)
N/A2 (5.6%)

Trials by Status

enrolling_by_invitation26%
withdrawn38%
terminated38%
completed1953%
unknown617%
recruiting26%
suspended13%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT06148025Phase 4

Antibiotics and Vaccine Immune Responses Study

Recruiting
NCT05539989Phase 1

Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn
NCT07005726Phase 4

BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa

Enrolling By Invitation
NCT06078891Early Phase 1

Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?

Enrolling By Invitation
NCT01697306Phase 2

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Completed
NCT04348370Phase 4

BCG Vaccine for Health Care Workers as Defense Against COVID 19

Completed
NCT04327206Phase 3

BCG Vaccination to Protect Healthcare Workers Against COVID-19

Completed
NCT04899765Phase 4

Measles and BCG Vaccines for Mother and Child

Recruiting
NCT05330884Phase 3

BCG Revaccination in Children and Adolescents

Suspended
NCT00352079Phase 3

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Terminated
NCT04659941Phase 2

Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers

Unknown
NCT04938323Phase 2

Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly

Withdrawn
NCT04328441Phase 3

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine

Completed
NCT04534803Phase 3

BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)

Withdrawn
NCT04414267Phase 4

Bacillus Calmette-guérin Vaccination to Prevent COVID-19

Completed
NCT03548233Not Applicable

BCG Vaccination Scar Formation in Children Under Five Years :Factors Affecting Its Formation and Subsequent Adverse Effects .

Unknown
NCT04461379Phase 3

Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers

Unknown
NCT04417335Phase 4

Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination

Unknown
NCT01878188Phase 1

Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Completed
NCT02444611Not Applicable

A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
36